Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.97 |
| ▸ | NPC1 | O15118 | 11/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.97 |
| ▸ | MAPT | P10636 | 6/20 | 0.97 |
| ▸ | HPGD | P15428 | 6/20 | 0.97 |
| ▸ | PKM | P14618 | 5/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.97 |
| ▸ | RELA | Q04206 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370639 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4725053 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24265257 | 0.86 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29402748 | 0.86 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12848495 | 0.84 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6390132 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12848787 | 0.83 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12848497 | 0.83 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6389879 | 0.81 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2932154 | 0.80 | ALDH1A3 (0.79) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381363-B1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-12-08 | — | — | EP | claimed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | claimed |
| US-6596731-B2 | An imidazo(1,2-a)pyridine derivative useful for treating chronical or acute neurological disorders, cognitive disorders and memory deficits | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | claimed |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | claimed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | claimed |
| US-6916826-B2 | Substituted imidazo[1,2-a]pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6861437-B2 | Substituted imidazo [1,2-a] pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1381363-B1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-12-08 | — | — | EP | disclosed |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | MUTEL VINCENT (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | disclosed |
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| US-6596731-B2 | An imidazo(1,2-a)pyridine derivative useful for treating chronical or acute neurological disorders, cognitive disorders and memory deficits | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | GRM5, GRM1, GRIK5 | RAB9A 982/4885NPC1 413/4885SMN1; SMN2 768/4885 |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | GRM5, GRM1, GRIK5 | RAB9A 982/4885NPC1 413/4885SMN1; SMN2 768/4885 |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | GRM5, GRM1, GRIK5 | RAB9A 982/4885NPC1 413/4885SMN1; SMN2 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.